Ionis Pharmaceuticals (Nasdaq: IONS) has presented new data from its Phase III NEURO-TTR study, evaluating inotersen in patients with a hereditary form of the rare disease ATTR amyloidosis.
The results, which are currently being presented at the first European ATTR Amyloidosis meeting in Paris, show significant benefit compared to placebo in both co-primary endpoints, after both eight and 15 months.
The efficacy of inotersen was measured according to a commonly-used quality of life assessment measure, and a disease severity assessment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze